0.52
-0.0339(-6.09%)
Currency In USD
Address
4200 Marathon Boulevard
Austin, TX 78756
United States of America
Phone
737 255 7194
Sector
Healthcare
Industry
Biotechnology
Employees
21
First IPO Date
July 11, 2001
| Name | Title | Pay | Year Born |
| Dr. Marc H. Hedrick M.B.A., M.D. | President, Chief Executive Officer & Director | 924,937 | 1963 |
| Mr. Andrew J. Sims CPA | Vice President of Finance & Chief Financial Officer | 546,358 | 1973 |
| Ms. Desiree Smith | Corporate Controller | 0 | 1964 |
| Dr. Michael Stanley Rosol Ph.D. | Chief Development Officer | 0 | 1969 |
| Mr. Russell W. Bradley | President & GM of CNSide Diagnostics | 0 | 1964 |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.